<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04160988</url>
  </required_header>
  <id_info>
    <org_study_id>QCR19002</org_study_id>
    <nct_id>NCT04160988</nct_id>
  </id_info>
  <brief_title>A Single-center, Retrospective Study to Evaluate the Clinical Performance of Artificial Intelligence Medical Assisted Diagnostic Software (VeriSee DR) for Screening of Diabetic Retinopathy in Patients With Diabetes Mellitus</brief_title>
  <official_title>A Single-center, Retrospective Study to Evaluate the Clinical Performance of Artificial Intelligence Medical Assisted Diagnostic Software (VeriSee DR) for Screening of Diabetic Retinopathy in Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acer Being Health Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acer Being Health Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the clinical performance of VeriSee DR for DR screening from color&#xD;
      fundus photography images in patients with diabetes mellitus. The sensitivity and specificity&#xD;
      of VeriSee DR's automated image analysis for screening the diabetes retinopathy will be&#xD;
      determined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Actual">May 11, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>2 months</time_frame>
    <description>To evaluate the clinical performance of VeriSee DR by determining the sensitivity.&#xD;
Sensitivity = 100% x TP/(TP+FN)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>2 months</time_frame>
    <description>To evaluate the clinical performance of VeriSee DR by determining the specificity.&#xD;
Specificity = 100% x TN/(TN+FP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive Predictive Values (PPV)</measure>
    <time_frame>2 months</time_frame>
    <description>To evaluate the clinical performance of VeriSee DR by determining the positive predictive values (PPV).&#xD;
Positive predictive value (PPV) =100% x TP/(TP+FP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Predictive Values (NPV)</measure>
    <time_frame>2 months</time_frame>
    <description>To evaluate the clinical performance of VeriSee DR by determining the negative predictive values (NPV).&#xD;
Negative predictive value (NPV) = 100% x TN/(FN+TN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participant Images With Insufficient Quality as Judged by VeriSee DR</measure>
    <time_frame>2 months</time_frame>
    <description>To determine the percentage of subjects' images with insufficient quality as judged by VeriSee DR.&#xD;
The percentage of subjects who have the images with insufficient quality as determined by VeriSee DR will be presented.</description>
  </secondary_outcome>
  <enrollment type="Actual">703</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Persons with diabetes, twenty years of age or older, who have been referred to an&#xD;
        ophthalmologists for a dilated eye examination to detect diabetic retinopathy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects enrolled in this study should meet all the following criteria.&#xD;
&#xD;
               1. Subject with age ≥ 20 years old&#xD;
&#xD;
               2. Subject with documented diagnosis of diabetes mellitus&#xD;
&#xD;
               3. Subject with image taken by color fundus photography that meet the following&#xD;
                  requirement:&#xD;
&#xD;
                    -  The resolution of image is 1024×1024 pixels or higher;&#xD;
&#xD;
                    -  The angle view of image is 45 or 50 degree.&#xD;
&#xD;
               4. Subject's image includes macula and optic nerve as judged by the ophthalmologist.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will be excluded if they meet any of the following criteria.&#xD;
&#xD;
               1. The color fundus photography image previously used by VeriSee DR during the&#xD;
                  development process and pre-clinical test&#xD;
&#xD;
               2. The macula, optic nerve, or other part in the image of color fundus photography&#xD;
                  is unclear to determine the disease condition as judged by the ophthalmologist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <results_first_submitted>November 19, 2020</results_first_submitted>
  <results_first_submitted_qc>January 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2021</results_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT04160988/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Group</title>
          <description>A total of 703 subjects with at least one qualified color fundus photography image as determined by the ophthalmologist were enrolled in this study. All 703 subjects enrolled were included in the intended use population. A total of 703 qualified color fundus photography images from all enrolled subjects were included for effectiveness analysis. No subjects were excluded from the intended use population.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="703"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="675"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>poor image quality</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intended Use Population</title>
          <description>Intended Use Population</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="703"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="703"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="703"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="354"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="703"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity</title>
        <description>To evaluate the clinical performance of VeriSee DR by determining the sensitivity.&#xD;
Sensitivity = 100% x TP/(TP+FN)</description>
        <time_frame>2 months</time_frame>
        <population>Of 703 subjects enrolled, VeriSee DR judged the images of 28 subjects (3.98%) as with insufficient image quality.</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Use Population</title>
            <description>Intended Use Population</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity</title>
          <description>To evaluate the clinical performance of VeriSee DR by determining the sensitivity.&#xD;
Sensitivity = 100% x TP/(TP+FN)</description>
          <population>Of 703 subjects enrolled, VeriSee DR judged the images of 28 subjects (3.98%) as with insufficient image quality.</population>
          <units>percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="675"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="92.48" upper_limit="96.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity</title>
        <description>To evaluate the clinical performance of VeriSee DR by determining the specificity.&#xD;
Specificity = 100% x TN/(TN+FP)</description>
        <time_frame>2 months</time_frame>
        <population>Of 703 subjects enrolled, VeriSee DR judged the images of 28 subjects (3.98%) as with insufficient image quality.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Group</title>
            <description>A total of 703 subjects with at least one qualified color fundus photography image as determined by the ophthalmologist were enrolled in this study. All 703 subjects enrolled were included in the intended use population. A total of 703 qualified color fundus photography images from all enrolled subjects were included for effectiveness analysis. No subjects were excluded from the intended use population.</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity</title>
          <description>To evaluate the clinical performance of VeriSee DR by determining the specificity.&#xD;
Specificity = 100% x TN/(TN+FP)</description>
          <population>Of 703 subjects enrolled, VeriSee DR judged the images of 28 subjects (3.98%) as with insufficient image quality.</population>
          <units>percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="675"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9" lower_limit="85.37" upper_limit="96.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Predictive Values (PPV)</title>
        <description>To evaluate the clinical performance of VeriSee DR by determining the positive predictive values (PPV).&#xD;
Positive predictive value (PPV) =100% x TP/(TP+FP)</description>
        <time_frame>2 months</time_frame>
        <population>Of 703 subjects enrolled, VeriSee DR judged the images of 28 subjects (3.98%) as with insufficient image quality.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Group</title>
            <description>A total of 703 subjects with at least one qualified color fundus photography image as determined by the ophthalmologist were enrolled in this study. All 703 subjects enrolled were included in the intended use population. A total of 703 qualified color fundus photography images from all enrolled subjects were included for effectiveness analysis. No subjects were excluded from the intended use population.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Predictive Values (PPV)</title>
          <description>To evaluate the clinical performance of VeriSee DR by determining the positive predictive values (PPV).&#xD;
Positive predictive value (PPV) =100% x TP/(TP+FP)</description>
          <population>Of 703 subjects enrolled, VeriSee DR judged the images of 28 subjects (3.98%) as with insufficient image quality.</population>
          <units>percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="675"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="91.97" upper_limit="96.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Negative Predictive Values (NPV)</title>
        <description>To evaluate the clinical performance of VeriSee DR by determining the negative predictive values (NPV).&#xD;
Negative predictive value (NPV) = 100% x TN/(FN+TN)</description>
        <time_frame>2 months</time_frame>
        <population>Of 703 subjects enrolled, VeriSee DR judged the images of 28 subjects (3.98%) as with insufficient image quality.</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Use Population</title>
            <description>Intended Use Population</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Predictive Values (NPV)</title>
          <description>To evaluate the clinical performance of VeriSee DR by determining the negative predictive values (NPV).&#xD;
Negative predictive value (NPV) = 100% x TN/(FN+TN)</description>
          <population>Of 703 subjects enrolled, VeriSee DR judged the images of 28 subjects (3.98%) as with insufficient image quality.</population>
          <units>percent</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="675"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" lower_limit="86.23" upper_limit="94.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participant Images With Insufficient Quality as Judged by VeriSee DR</title>
        <description>To determine the percentage of subjects' images with insufficient quality as judged by VeriSee DR.&#xD;
The percentage of subjects who have the images with insufficient quality as determined by VeriSee DR will be presented.</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intended Use Population</title>
            <description>Intended Use Population</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participant Images With Insufficient Quality as Judged by VeriSee DR</title>
          <description>To determine the percentage of subjects' images with insufficient quality as judged by VeriSee DR.&#xD;
The percentage of subjects who have the images with insufficient quality as determined by VeriSee DR will be presented.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="703"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>this study is a retrospective study so there is no need to collect adverse event data.</time_frame>
      <desc>this study is a retrospective study so there is no need to collect adverse event data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Test Group</title>
          <description>A total of 703 subjects with at least one qualified color fundus photography image as determined by the ophthalmologist were enrolled in this study. All 703 subjects enrolled were included in the intended use population. A total of 703 qualified color fundus photography images from all enrolled subjects were included for effectiveness analysis. No subjects were excluded from the intended use population.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Regulator Manager</name_or_title>
      <organization>Acer Healthcare Inc.</organization>
      <phone>886-6-26963131 ext 5789</phone>
      <email>Johnny.Lu@acer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

